Grufity logo
Grufity logo
ATNM

ATNM - Actinium Pharmaceuticals Inc Stock Price, Fair Value and News

$1.25-0.15 (-10.71%)
Market Closed as of 14 Sep 2026, 04:00 pm ET

ATNM Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ATNM Price Action

Last 7 days

21.4%

Last 30 days

20.2%

Last 90 days

27.6%

Trailing 12 Months

-23.3%

ATNM RSI Chart

ATNM Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ATNM Valuation

Market Cap

39.3M

Price/Earnings (Trailing)

3.48

Price/Sales (Trailing)

310.53

Price/Free Cashflow

-1.1

ATNM Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ATNM Fundamentals

ATNM Revenue

Revenue (TTM)

81.0K

ATNM Earnings

Earnings (TTM)

11.3M

Earnings Growth (Yr)

505.66%

Earnings Growth (Qtr)

605.27%

ATNM Profitability

Return on Equity

37.32%

Return on Assets

28.16%

Free Cashflow Yield

-90.51%

ATNM Investor Care

Shares Dilution (1Y)

0.79%

Diluted EPS (TTM)

0.36

Revenue & Growth

How Actinium Pharmaceuticals Inc generates revenue and covers its expenses, based on the latest reported earnings.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2026----
2025----
2024----
2023---81.0K
2022---1.0M
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Actinium Pharmaceuticals Inc

ATNM
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple targets in oncology and hematology, including CD45, CD33, HER3, and other. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company is based in New York, New York.
 CEO
 WEBSITEactiniumpharma.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES49

Actinium Pharmaceuticals Inc Frequently Asked Questions

ATNM is the stock ticker symbol of Actinium Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Mon Sep 14 2026, market cap of Actinium Pharmaceuticals Inc is 39.3 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Mon Sep 14 2026, ATNM's PE ratio (Price to Earnings) is 3.48 and Price to Sales (PS) ratio is 310.53. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ATNM PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Actinium Pharmaceuticals Inc has provided -0.309 (multiply by 100 for percentage) rate of return.